3Neutel JM. Beyond the sphyonomanometric numbers : hypertension as a syndrome [J]. Am J Hypertens, 2001, 14 (8 Pt 2) :250S -257S.
4Virdis A, Ghiadoni L, Sudano I, et al. Endothelial function in hypertension : role of gender [ J ]. J Hypertens Suppl, 2002, 20 ( 2 ) :S11 -S16.
5Hlubocka Z, Umnerova V, Heller S, et al. Is mild essential hypertension without obvious organ complications and risk factors associated with increased levels of circulating markers of endothelial dysfunction? [J]. Vnitr Lek, 2002, 48 (8) : 718 -723.
6McEwan PE, Sherry L, Kenyon C J, et al. Regulation of the myocardial endothelin system by angiotensin-Ⅱ and Losartan [ J]. J Cardiovasc Pharmacol, 2000, 36 (5 Suppl 1): S144-S147.
7Nadar SK, Al Yemeni E, Blann AD, et al. Thrombomodulin, von Willebrand factor and E-selectin as plasma markers of endothelial damage/dysfunction and activation in pregnancy induced hypertension [J]. Thromb Res, 2004, 113 (2) :123 -128.
8Galatius S, Wroblewski H, Sorensen VB, et al. Endothelin and von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation? [J]. Am Heart J, 1999, 137 (3) : 549 -554.
9Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential [J]. Cardiovasc Res, 2002, 55 (2) : 250- 260.
10Nadar S, Lip GY. The prothrombotie state in hypertension and the effects of antihypertensive treatment [ J ]. Curr Pharm Des, 2003, 9 (21) :1715 - 1732.
